Latest Conference Articles

Samsung Bioepis Reports Long-term Ontruzant Findings for HER2-Positive Breast Cancer

Tony Hagen

September 14 2021

The positive findings for the trastuzumab biosimilar Ontruzant in patients with human epidermal growth factor receptor 2 (HER2)–positive early or locally advanced breast cancer were presented at the European Society for Medical Oncology (ESMO) Congress 2021.

Investigators Elucidate ADA Predictive Value of Infliximab Clearance in Crohn Disease

Tony Hagen

July 26 2021

Concomitant use of immunomodulators and dosage are important variables in the development of antidrug antibodies (ADAs) for patients receiving infliximab for Crohn disease, investigators report.

Investigators Report Findings on Infliximab Switching in IBD

Tony Hagen

July 21 2021

Pharmacokinetic, safety, and efficacy findings for patients with inflammatory bowel disease (IBD) were presented at the European Crohn's and Colitis Organization's annual meeting.

ACI Panelists Discuss Misaligned Incentives in the Biosimilars Market

Tony Hagen

July 15 2021

Panelists at the American Conference Institute's 2021 meeting took on the complexities of biosimilar adoption in a wide-ranging discussion.

Adalimumab Biosimilar Transition Studies Reported at ECCO'21 Congress

Tony Hagen

July 13 2021

Presentations at the European Crohn's and Colitis Organization annual meeting supported the transition to adalimumab biosimilars and provided patient acceptance data.

Truxima Produces Savings and Comparable Outcomes for UK Patients With CLL, NHL

Tony Hagen

June 30 2021

Investigators reported high overall response rates and savings of roughly $1400 per patient across cohorts.

Budget Model Predicts Savings for Switch to Rituximab Biosimilar in NHL, CLL

June 26 2021

Sizeable savings per patient with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) were anticipated by a Medicare savings model.

Amgen Executive Weighs the Challenges for Interchangeable Biosimilars

Tony Hagen

June 25 2021

A turning point for interchangeable biosimilars has arrived, as the first may be approved this year, but many questions about these agents have yet to be answered, according to Laura Sim, senior counsel for Amgen.

Poll: What Were the Most Important Biosimilar Findings Presented at ASCO?

June 23 2021

Diverse findings on biosimilar safety and savings were presented at the American Society for Clinical Oncology (ASCO) 2021 Annual Meeting.

Pharmaceutical Pay-for-Delay Settlements "Have a Good Side"

Tony Hagen

June 23 2021

Pay-for-delay settlements between drug companies are better regulated than in the past and are in danger of being overregulated, one panelist said.